Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the company’s £1.25 million fundraise and its expanding focus on central nervous system (CNS) drug development.
Tennyson said the new capital—raised from strategic and institutional investors—brings Solvonis’s total fundraising since May to £4.25 million. These funds will support the acceleration of its CNS discovery programme, which he described as “the innovation engine that drives long-term value creation for Solvonis Therapeutics PLC.”
The company is building a platform centred on addiction, psychiatry, and neurology, with a particular focus on high-burden, poorly treated diseases. Solvonis already has an advanced clinical programme for severe alcohol use disorder (SVN-001), targeting the UK and EU markets. A phase 2b trial is also planned for SVN-002, aimed at moderate to severe alcohol use disorder in the US.
Looking ahead, Tennyson outlined a three-tiered value strategy, covering near-, medium-, and long-term milestones. He said the company follows a lean, capital-efficient model, working with CROs and academic groups to advance its assets to key inflection points for potential out-licensing to larger pharmaceutical partners.
“Our business model is focused on progressing our assets to the appropriate inflection point and then seeking to end-license those,” Tennyson explained.
Visit Proactive’s YouTube channel for more interviews like this. Don’t forget to like this video, subscribe, and enable notifications for future updates.
#SolvonisTherapeutics #BiotechNews #CNSDisorders #AlcoholUseDisorder #SVN001 #SVN002 #Biopharma #DrugDiscovery #Neuroscience #MentalHealth #InvestorUpdates #PharmaceuticalDevelopment #CapitalRaise
